✦ LIBER ✦

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

✍ Scribed by DeAngelo, Daniel J.; Attar, Eyal C.

Book ID: 126136436
Publisher: Informa plc
Year: 2009
Tongue: English
Weight: 324 KB
Volume: 51
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428190903518295

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 Cost-Effectiveness Analysis of Nil

PCN13 Cost-Effectiveness Analysis of Nilotinib Versus Dasatinib in Patients With Imatinib-Resistant or Imatinib-Intolerant Chronic Myeloid Leukemia (CML)

✍ Niu, X.; Hay, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Cost-Utility Analysis of Dasatinib and N

Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand

✍ Kulpeng, Wantanee; Sompitak, Sumalai; Jootar, Saengsuree; Chansung, Kanchana; Te 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 433 KB

PCN99 Cost-Effectiveness of Dasatinib ve

PCN99 Cost-Effectiveness of Dasatinib versus High-Dose Imatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia Resistant to Standard-Dose Imatinib in Portugal

✍ Darba, J.; Kaskens, L.; Abecasis, M.; Vitorino, R.; Carrasco, J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH